DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-907

Novo Nordisk Pharmaceuticals
Attention: MaryAnne McElligott, Ph.D.
Regulatory Affairs
100 Overlook Center, Suite 200
Princeton, NJ 08540-7810

NOV 18 1998

Dear Dr. McElligott:

Please refer to your new drug application (NDA) dated November 7, 1997, received November 19, 1997, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Activelle™ (estradiol/norethindrone acetate tablets).

We acknowledge receipt of your submissions dated December 16, 1997, and January 9, March 18, 19, and 25, July 8, 10, and 22, September 14, October 14 and 28, and November 3, 6 (3), 11, 17 and 18 (2), 1998.

This new drug application provides for the use of Activelle™ (estradiol/norethindrone acetate tablets) for the treatment of moderate to severe vasomotor symptoms associated with the menopause and in the treatment of vulvar and vaginal atrophy in women with an intact uterus.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the draft physician and patient labeling dated November 18, 1998, and the draft carton and container labels dated November 6, 1998. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 20-907." Approval of this submission by the Food and Drug Administration is not required before the labeling is used.

We remind you of your Phase 4 commitment specified in your submission dated November 6, 1998.

Submit protocols, data, and final reports related to this Phase 4 commitment to this NDA as correspondence. In addition, under 21 CFR 314.82(b)(2)(vii), we request that you include a status summary of your commitment in the annual report to this NDA. For administrative purposes, all submissions relating to this Phase 4 commitment should be clearly designated "Phase 4 Commitment."

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Reproductive and Urologic Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Jennifer Mercier, Project Manager, at (301) 827-4260.

Sincerely,

Florence Houn, M.D., M.P.H.
Deputy Director
Office of Drug Evaluation II
Center for Drug Evaluation and Research